Why Clever Leaves Holdings Shares Are Trading Lower By Around 60%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Written by Emily J. Thompson, Senior Investment Analyst
Source: Benzinga
- Clever Leaves Holdings Delisting: Clever Leaves Holdings Inc. CLVR saw a sharp decline in shares after announcing voluntary delisting from Nasdaq and deregistering its securities.
- Stocks on the Move: Various companies experienced significant stock movements during Monday's mid-day session, with some notable gainers and decliners.
- Gainers: Companies like Deciphera Pharmaceuticals, ImmunityBio, Koninklijke Philips N.V., and Soleno Therapeutics saw notable increases in their stock prices.
- Losers: Stocks such as Annovis Bio, Addex Therapeutics Ltd, and Nature Wood Group Limited faced declines in their share prices.
- Market Updates: Other news included Tesla partnering with Baidu for mapping in China, and Deutsche Bank facing potential litigation costs up to €1.3 billion.
Analyst Views on ANVS
Wall Street analysts forecast ANVS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ANVS is 11.67 USD with a low forecast of 8.00 USD and a high forecast of 17.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Analyst Rating
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 3.200
Low
8.00
Averages
11.67
High
17.00
Current: 3.200
Low
8.00
Averages
11.67
High
17.00
About ANVS
Annovis Bio, Inc. is a late-stage clinical drug platform company addressing neurodegeneration such as Alzheimer’s disease (AD), and Parkinson’s disease (PD). The Company is developing its lead product candidate, Buntanetap, which is designed to address AD, PD, and potentially other chronic neurodegenerative diseases. Buntanetap is a synthetically produced small molecule, orally administered, brain penetrant compound. Its product candidate ANVS405 is an intravenous drug being developed for acute indications and focused on protecting the brain after traumatic brain injury and/or stroke. ANVS405 is the same compound as Buntanetap, given in cases of acute head and brain trauma. ANVS301 is an orally administered drug being developed to increase cognitive capability in later stages of AD and dementia. ANVS301 is observed to improve memory and learning in very old rats by lowering the number of errors from over six to three.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
